Cargando…

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells

Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobhakumari, Arya, Orcutt, Kevin P., Love-Homan, Laurie, Kowalski, Christopher E., Parsons, Arlene D., Knudson, C. Michael, Simons, Andrean L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282972/ https://www.ncbi.nlm.nih.gov/pubmed/27178822 http://dx.doi.org/10.3727/096504016X14586627440192

Ejemplares similares

Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism
por: Sobhakumari, Arya, et al.
Publicado: (2012)

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
por: Stanam, Aditya, et al.
Publicado: (2016)

Inhibition of Glutathione and Thioredoxin Metabolism Enhances Sensitivity to Perifosine in Head and Neck Cancer Cells
por: Simons, Andrean L., et al.
Publicado: (2009)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report
por: Thinn, Mie Mie, et al.
Publicado: (2019)

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
por: Liu, Shuli, et al.
Publicado: (2020)

Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
por: Ngan, Hoi-Lam, et al.
Publicado: (2020)

Antitumor effects of erlotinib in combination with berberine in A431 cells
por: Cuan, Xiangdan, et al.
Publicado: (2023)

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
por: Jain, Ankit P., et al.
Publicado: (2019)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Cancer stem cells in head and neck squamous cell carcinoma
por: Karamboulas, Christina, et al.
Publicado: (2013)

Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma
por: Kumai, Takumi, et al.
Publicado: (2015)

Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma
por: Xie, Guiqin, et al.
Publicado: (2022)

Common patterns of perineural spread in head-neck squamous cell carcinoma identified on fluoro-deoxy-glucose positron emission tomography/computed tomography
por: Chandra, Piyush, et al.
Publicado: (2016)

MAPK1(E322K) mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin
por: Wen, Yihui, et al.
Publicado: (2016)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases
por: Read, William L., et al.
Publicado: (2015)

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
por: Lee, Jeongjae, et al.
Publicado: (2022)

Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells
por: Kleszcz, Robert, et al.
Publicado: (2023)

The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma
por: Zhou, Chumin, et al.
Publicado: (2020)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck
por: Henriksson, Eva, et al.
Publicado: (2009)

Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
por: Li, Rui, et al.
Publicado: (2013)

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma
por: Jiang, Minghong, et al.
Publicado: (2011)

Comparative Antitumor Activity and Intestinal Toxicity of 5′‐Deoxy‐5‐fluorouridine and Its Prodrug Trimethoxybenzoyl‐5′‐deoxy‐5‐fluorocytidine
por: Ninomiya, Yasuyuki, et al.
Publicado: (1990)

Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing Mice
por: Wang, Peipei, et al.
Publicado: (2014)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
por: Murányi, József, et al.
Publicado: (2023)

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status
por: Porosnicu, Mercedes, et al.
Publicado: (2022)

Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma
por: Hill, Rhianna M., et al.
Publicado: (2022)

Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
por: Kono, Michihisa, et al.
Publicado: (2022)

Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7
por: Kalinowski, Felicity C., et al.
Publicado: (2012)

Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
por: Deng, Peng, et al.
Publicado: (2022)

Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype
por: VATU, BOGDAN IONEL, et al.
Publicado: (2020)

Genomic profile of a squamous cell carcinoma ex pleomorphic adenoma compared to a head and neck squamous cell carcinoma()
por: Mariano, Fernanda Viviane, et al.
Publicado: (2016)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Cutaneous Squamous Cell Carcinoma of the Head and Neck
por: Gurudutt, Vivek V., et al.
Publicado: (2011)

Hypoxia in Head and Neck Squamous Cell Carcinoma
por: Li, John Zenghong, et al.
Publicado: (2012)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mo3u5k5rt7ujntlgeguknk6a02